HomeCONGRESS

CONGRESS

ESC 2023 | Anticoagulation After Primary PCI in STEMI Patients

The empirical prescription of anticoagulants after percutaneous coronary intervention (PCI), also know as post-procedural anticoagulation (PPA), is...

ESC 2023 | Extended Monotherapy with Clopidogrel vs. DAPT in High-Risk Patients

An increasing number of patients currently present both an elevated ischemic risk and hemorrhagic risk. This means...

ESC 2023 | ECLS-Shock

Cardiogenic shock (CS) represents the main cause of death in patients hospitalized for acute myocardial infarction (AMI)....

ESC 2023 | STOPDAPT-3 

Short Dual antiplatelet therapy (DAPT), one to three months, followed by P2Y12 inhibitor monotherapy has been shown...

ESC 2023 | FIRE-Trial: Physiology Guided Complete Revascularization Benefits Elderly Patients with Myocardial Infarction

Patients over 75 with acute coronary syndrome (ACS) are often badly represented in most significant studies.  In this...

ESC 2023 | BUDAPEST CRT Upgrade trial

Approximately 1 million pacemakers (PM) or Implantable cardioverter-defibrillators (ICDs) are placed every year around the world, and...

ESC 2023 | OCTOBER TRIAL: Should We Begin to Consider OCT for Bifurcation Lesions?

The OCTOBER Study randomized 1201 patients with bifurcation lesions in a 1:1 ratio to undergo percutaneous transluminal...

ESC 2023 | ILUMIEN IV: What Is the Benefit of OCT?

Researchers conducted a randomized study that included a total of 1233 patients who underwent percutaneous transluminal coronary...